Download PDF
Horm Metab Res 2006; 38(12): 812-816
DOI: 10.1055/s-2006-956500
Original Clinical

© Georg Thieme Verlag KG Stuttgart · New York

Effect of Angiotensin Converting Enzyme Inhibitors on 1.25-(OH)2 D Levels of Hypertensive Patients. Relationship with ACE Polymorphisms

J. L. Pérez-Castrillón 1 , I. Justo 1 , A. Sanz 2 , D. De Luis 1 , A. Dueñas 1
  • 1Departamento de Medicina Interna, Hospital Universitario Río Hortega, Facultad de Medicina de Valladolid, Valladolid, Spain
  • 2Laboratorio de Pediatría, Departamento de Pediatría-IBGM, Facultad de Medicina de Valladolid, Valladolid, Spain
Further Information

Publication History

Received 9 March 2006

Accepted after revision 24 July 2006

Publication Date:
12 December 2006 (online)

Also available at
    Permissions and Reprints

Abstract

Background: The effect of angiotensin converting enzyme inhibitors (ACEIs) on 1.25-dihydroxyvitamin D 1.25-(OH)2D levels has not been studied. The purpose of this study is to assess the relationship between 1.25-dihydroxyvitamin D levels and I/D angiotensin-converting enzyme polymorphism (ACE) in hypertensive patients. Materials and Methods: The study included 60 individuals (31 females and 29 males) with systolic and/or diastolic hypertension. The 25-hydroxyvitamin D levels were measured by HPLC and the 1.25-(OH)2 D was determined by RIA. ACE polymorphism was analyzed by Polymerase Chain Reaction (PCR) using a modification of the original method described by Rigat. Results: Treatment with ACEIs produced an increase in total calcium (p=0.003) and a decrease in the 1.25-(OH)2 D (p=0.0001). No relationship between final calcium and 1.25-(OH)2 D (r=-0.171, p=0.198) was observed. When the effects of enalapril and quinapril were analyzed separately, the results were similar. When the patients were divided according to genotype, the decrease in 1.25-(OH)2 D was observed only in patients with D allele, genotype Ins/Del (69±23 vs. 48±19, p=0.021 ) and in those of genotype Del/Del (64±19 vs. 17, p=0.004). Conclusion: The ACE inhibitors in combination with the presence of the DD genotype decrease the level of 1.25-(OH)2 D. There was no difference between enalapril and quinapril treated groups.

Key words

1.25-Dihydroxyvitamin D - hypertension - angiotentensin converting enzyme - insertion/deletion polymorphism

References

  • 1 Sigmund CD. Regulation of renin expression and blood pressure by Vitamin D3.  J Clin Invest. 2002;  110 155-156
    CrossrefPubMedGoogle Scholar
  • 2 Giner V, Corella D, Chaves FJ, Pascual JM, Portoles O, Marin P, Lozano JV, Armengod ME, Redon J. Polimorfismos genéticos del sistema renina-angiotensina e hipertensión arterial esencial en la población española.  Med Clin (Barc). 2001;  117 525-529
    PubMedGoogle Scholar
  • 3 Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, Schunkert H. Angiotensin converting enzyme in the human heart effect of the deletion/insertion polymorphism.  Circulation. 1995;  92 1387-1388
    CrossrefPubMedGoogle Scholar
  • 4 Fray JC, Park CS, Valentine AN. Calcium and the control of renin secretion.  Endocr Rev. 1987;  8 53-93
    PubMedGoogle Scholar
  • 5 Burgess ED, Hawkins RG, Wanatabe M. Interaction of 1,25-dihydroxivitamin D and plasma renin activity in high renin essential hypertension.  Am J Hypertens. 1990;  3 903-905
    PubMedGoogle Scholar
  • 6 Resnick LM, Muller FB, Laragh JH. Calcium regulating hormones in essential hypertension: relation to plasma renin activity and sodium metabolism.  Ann Int Med. 1986;  105 649-654
    PubMedGoogle Scholar
  • 7 Puig JG, Mateos FA, Ramos TH, Lavilla MP, Capitan MC, Gil A. Albumin excretion rate and metabolic modifications in patients with essential hypertension. Effects of two angiotensin converting enzyme inhibitors.  Am J Hypertens. 1994;  7 46-51
    PubMedGoogle Scholar
  • 8 John SW, Weitzner G, Rozen R, Scriver CR. A rapid method for extracting genomic DNA from leukocytes.  Nucleic Acids Res. 1991;  19 408
    PubMedGoogle Scholar
  • 9 Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes.  PCR Methods Appl. 1993;  3 120-121
    PubMedGoogle Scholar
  • 10 Rigat B, Hubert P, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1 dipeptidyl carboxypeptidase 1).  Nucleic Acids Res. 1992;  20 1433
    PubMedGoogle Scholar
  • 11 Perna NT, Batzer MA, Deininger PL, Stoneking M. Alu insertion polymorphism: A new type of marker for human population studies.  Hum Biol. 1992;  64 641-648
    PubMedGoogle Scholar
  • 12 Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.  Endocr Rev. 2001;  22 477-501
    CrossrefPubMedGoogle Scholar
  • 13 Li CY, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system.  J Clin Invest. 2002;  110 229-238
    CrossrefPubMedGoogle Scholar
  • 14 Inui N, Murayama A, Sasaki S, Suda T, Chida K, Kato S, Nakamura H. Correlation between 25-hydroxyvitamin D3 1α-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis.  Am J Med. 2001;  110 687-693
    CrossrefPubMedGoogle Scholar
  • 15 Wolf G, Bohlender J, Bondeva T, Roger T, Thaiss F, Wenzel UO. Angiotensin II Upregulates Toll-Like Receptor 4 on Mesangial Cells.  J Am Soc Nephrol. 2006;  , (E-pub ahead)
    PubMedGoogle Scholar
  • 16 Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.  Science. 2006;  311 1770-1773
    CrossrefPubMedGoogle Scholar
  • 17 Krystal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men.  Hypertension. 1997;  30 1289-1294
    PubMedGoogle Scholar
  • 18 Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid levels in elderly women.  J Clin Endocrinol Metab. 2001;  86 1633-1637
    CrossrefPubMedGoogle Scholar
  • 19 Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group . Meta-Analysis of the efficacy of Vitamin D treatment in preventing osteoporosis in postmenopausal women.  Endocr Rev. 2002;  23 560-569
    CrossrefPubMedGoogle Scholar
  • 20 Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.  Endocr Rev. 1999;  20 345-357
    CrossrefPubMedGoogle Scholar
  • 21 Itonaga I, Sabokbar A, Neale SD, Athanasou NA. 1,25-Dihydroxyvitamin D3 and prostaglandin E(2) act directly on circulating human osteoclast precursors.  Biochem Biophys Res Commun. 1999;  264 590-595
    CrossrefPubMedGoogle Scholar
  • 22 Perez-Castrillon JL, Silva J, Justo I, Sanz A, Martin-Luquero M, Igea R, Escudero P, Pueyo C, Diaz C, Hernandez G, Duenas A. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: Relationship with angiotensin converting enzyme polymorphisms.  Am J Hypertens. 2003;  16 453-459
    CrossrefPubMedGoogle Scholar

Correspondence

José L. Pérez-Castrillón

Hospital Río Hortega

Cardenal Torquemada s/n

47010 Valladolid

Spain

Phone: +34/983/42 04 00

Fax: +34/983/33 15 66

Email: castrv@terra.es

      >